iBio, Inc. (IBIO)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$47.9M
Cash & Equivalents
$17.0M
Quarterly Burn Rate
8 mo
Est. Cash Runway
$75M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2027-05-01 Phase1 Readout —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT07487376 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Ove... PHASE1 Recruiting 32

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for IBIO.

SEC EDGAR Filings

All SEC filings for iBio, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.